IP Library › Granted Patent US 12662453
Granted Patent B2
US 12662453 · App. 17/846,830 · Granted Jun 23, 2026

Heterocyclic compound and use thereof

Inventors: Yuichi Kajita (Kanagawa, JP); Yuhei Miyanohana (Kanagawa, JP); Tatsuki Koike (Kanagawa, JP); Kohei Takeuchi (Kanagawa, JP); Yoshiteru Ito (Kanagawa, JP); Norihito Tokunaga (Kanagawa, JP); Takahiro Sugimoto (Kanagawa, JP); Tohru Miyazaki (Kanagawa, JP); Tsuneo Oda (Kanagawa, JP); Yasutaka Hoashi (Kanagawa, JP); Yasushi Hattori (Kanagawa, JP); Keisuke Imamura (Kanagawa, JP)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
C07D211/56A61P25/00A61P25/26C07D205/04C07D207/14C07D211/36C07D401/06C07D401/10C07D401/14C07D403/06C07D405/06C07D405/10C07D405/12C07D409/10C07D413/06C07D417/06C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662453
App. No.
17/846,830
Granted
Jun 23, 2026
Kind
B2
Abstract

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Claims (16)

1 . A method of activating an orexin type 2 receptor in a mammal, which comprises administering an effective amount of a compound selected from

N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide;

N-((2S,3S)-2-((2,3′-difluorobiphenyl-3-yl)methyl)-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl)ethanesulfonamide; and

N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)ethanesulfonamide;

or a salt thereof, to the mammal.

2 . The method of claim 1 , wherein the compound is N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide, or a salt thereof.

3 . The method of claim 1 , wherein the compound is N-((2S,3S)-2-((2,3′-difluorobiphenyl-3-yl)methyl)-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl)ethanesulfonamide, or a salt thereof.

4 . The method of claim 1 , wherein the compound is N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)ethanesulfonamide, or a salt thereof.

5 . A method for the prophylaxis or treatment of narcolepsy in a mammal, which comprises administering an effective amount of a compound selected from:

N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide;

N-((2S,3S)-2-((2,3′-difluorobiphenyl-3-yl)methyl)-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl)ethanesulfonamide; and

N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)ethanesulfonamide;

or a salt thereof, to the mammal.

6 . The method of claim 5 , wherein the compound is N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide, or a salt thereof.

7 . The method of claim 5 , wherein the compound is N-((2S,3S)-2-((2,3′-difluorobiphenyl-3-yl)methyl)-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl)ethanesulfonamide, or a salt thereof.

8 . The method of claim 5 , wherein the compound is N-((2S,3S)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3′,5′-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)ethanesulfonamide, or a salt thereof.